Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11980687 | 0.88 | ALDH1A1 (0.50) | POLBTDP1CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL19442077 | 0.87 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL11980681 | 0.84 | MEN1 (0.46) | POLBCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL11980684 | 0.84 | ALDH1A1 (0.43) | POLBTDP1CYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL11980685 | 0.79 | ABHD6 (0.51) | POLBTDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL991710 | 0.78 | MEN1 (0.51) | POLBTDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL11980682 | 0.76 | RAB9A (0.46) | POLBALDH1A1KMT2ATP53TSHR | |
| SCHEMBL11985068 | 0.75 | ALDH1A1 (0.39) | POLBTDP1ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL11980704 | 0.74 | RAB9A (0.64) | POLBTDP1ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL11985253 | 0.72 | MAPT (0.42) | POLBCYP2C9CYP2C19ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA (CANADA) INC (US) | 2016-11-24 | — | — | US | disclosed |
| US-9434718-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150025069-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2015-01-22 | — | — | US | disclosed |
| US-8884034-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025069-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | POLB 899/4885TDP1 3363/4885CYP1A2 132/4885 |
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | POLB 899/4885TDP1 3363/4885CYP1A2 132/4885 |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | POLB 750/4885TDP1 3323/4885CYP1A2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.